$PTCT
PTC THERAPEUTICS, INC. Stock $ptct

$ptct Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-K Financial Statement

#000104746914001914 Filed on March 06, 2014

Income Statement

Concept	2014 Q1	2013 Q4	2013 Q3
Revenue	$9.217M	$4.411M	$16.29M
YoY Change	29.05%	-33.57%	126.4%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.500M	$7.500M	$6.700M
YoY Change	66.67%	134.38%	76.32%
% of Gross Profit
Research & Development	$15.89M	$15.00M	$13.89M
YoY Change	41.15%	57.89%	32.67%
% of Gross Profit
Depreciation & Amortization	$588.0K	$590.0K	$590.0K
YoY Change	-5.92%	-9.23%	-11.94%
% of Gross Profit
Operating Expenses	$23.43M	$22.50M	$20.57M
YoY Change	49.06%	77.55%	44.31%
Operating Profit	-$14.21M	-$18.09M	-$4.276M
YoY Change	65.72%	199.82%	-39.4%
Interest Expense	$171.0K	$200.0K	$26.70K
YoY Change	-102.78%	-200.0%	-110.79%
% of Operating Profit
Other Income/Expense, Net	-$57.00K	$0.00	-$37.62K
YoY Change	-205.56%		-783.06%
Pretax Income	-$14.10M	-$17.90M	-$4.400M
YoY Change	-4.08%	184.13%	-39.73%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$14.10M	-$17.89M	-$4.416M
YoY Change	-3.99%	185.17%	-39.48%
Net Earnings / Revenue	-152.96%	-405.5%	-27.11%
Basic Earnings Per Share		-$0.75	-$0.19
Diluted Earnings Per Share	-$575.5K	-$0.75	-$0.19
COMMON SHARES
Basic Shares Outstanding	30.08M shares	24.92M shares	23.80M shares
Diluted Shares Outstanding			23.80M shares

Balance Sheet

Concept	2014 Q1	2013 Q4	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$246.6M	$142.5M	$157.2M
YoY Change	391.24%	5127.44%
Cash & Equivalents	$115.9M	$15.41M	$24.04M
Short-Term Investments	$130.7M	$127.1M	$133.2M
Other Short-Term Assets	$2.000M	$1.600M	$2.100M
YoY Change	122.22%
Inventory
Prepaid Expenses
Receivables	$800.0K	$1.000M	$800.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$249.4M	$145.0M	$160.1M
YoY Change	378.66%	3055.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.328M	$6.730M	$6.943M
YoY Change	-17.82%	-18.72%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$100.0K	$200.0K
YoY Change	-50.0%
Total Long-Term Assets	$6.460M	$6.879M	$7.106M
YoY Change	-17.18%	-18.85%
TOTAL ASSETS
Total Short-Term Assets	$249.4M	$145.0M	$160.1M
Total Long-Term Assets	$6.460M	$6.879M	$7.106M
Total Assets	$255.8M	$151.9M	$167.2M
YoY Change	327.11%	1062.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$387.0K	$1.124M	$1.017M
YoY Change	29.0%	80.83%
Accrued Expenses	$2.100M	$5.100M	$3.100M
YoY Change	-48.78%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$12.00K	$49.00K	$84.23K
YoY Change	-99.68%	-98.9%
Total Short-Term Liabilities	$9.239M	$13.13M	$13.92M
YoY Change	-66.16%	-53.36%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$2.259M	$2.227M	$2.290M
YoY Change	-24.7%	-12.66%
Total Long-Term Liabilities	$2.259M	$2.227M	$2.290M
YoY Change	-24.7%	-25.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.239M	$13.13M	$13.92M
Total Long-Term Liabilities	$2.259M	$2.227M	$2.290M
Total Liabilities	$11.50M	$15.36M	$16.21M
YoY Change	-62.05%	-51.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$342.9M	-$328.8M	-$310.9M
YoY Change		18.6%
Common Stock	$30.00K	$24.00K	$24.34K
YoY Change		4303.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$244.3M	$136.5M	$151.0M
YoY Change
Total Liabilities & Shareholders Equity	$255.8M	$151.9M	$167.2M
YoY Change	327.11%	1062.02%

Cashflow Statement

Concept	2014 Q1	2013 Q4	2013 Q3
OPERATING ACTIVITIES
Net Income	-$14.10M	-$17.89M	-$4.416M
YoY Change	-3.99%	185.17%	-39.48%
Depreciation, Depletion And Amortization	$588.0K	$590.0K	$590.0K
YoY Change	-5.92%	-9.23%	-11.94%
Cash From Operating Activities	-$13.44M	-$14.46M	-$5.180M
YoY Change	71.21%	30.98%	-16.45%
INVESTING ACTIVITIES
Capital Expenditures	$186.0K	-$380.0K	-$370.0K
YoY Change	785.71%	3700.0%
Acquisitions
YoY Change
Other Investing Activities	-$4.080M	$6.240M	-$121.6M
YoY Change
Cash From Investing Activities	-$4.270M	$5.870M	-$122.0M
YoY Change	21250.0%	-58800.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$37.00K
YoY Change	-96.54%
Cash From Financing Activities	118.2M	-30.00K	-2.860M
YoY Change	113.31%	-95.71%	81.01%
NET CHANGE
Cash From Operating Activities	-13.44M	-14.46M	-5.180M
Cash From Investing Activities	-4.270M	5.870M	-122.0M
Cash From Financing Activities	118.2M	-30.00K	-2.860M
Net Change In Cash	100.4M	-8.620M	-130.1M
YoY Change	111.36%	-26.64%	1571.72%
FREE CASH FLOW
Cash From Operating Activities	-$13.44M	-$14.46M	-$5.180M
Capital Expenditures	$186.0K	-$380.0K	-$370.0K
Free Cash Flow	-$13.63M	-$14.08M	-$4.810M
YoY Change	73.12%	27.65%	-22.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-6597861	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-6068072	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-7297125	USD
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	-6272044	USD
CY2012Q2	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	159954069	USD
CY2012Q2	us-gaap	Preferred Stock Conversions Inducements PreferredStockConversionsInducements	377787	USD
CY2012Q1	us-gaap	Profit Loss ProfitLoss	-6597861	USD
CY2012Q2	us-gaap	Profit Loss ProfitLoss	153508210	USD
CY2012Q3	us-gaap	Profit Loss ProfitLoss	-7297125	USD
CY2012Q4	us-gaap	Profit Loss ProfitLoss	-6272044	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1599200	USD
CY2013Q4	ptct	Grant And Other Receivables GrantAndOtherReceivables	957722	USD
CY2013Q4	ptct	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	149008	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	48622	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	877434	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2226970	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	24344	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	465245968	USD
CY2013	ptct	Collaboration Revenue CollaborationRevenue	31326117	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25218652	USD
CY2013	us-gaap	Revenue From Grants RevenueFromGrants	3370210	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	54875144	USD
CY2013	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-6083655	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	37512	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-51573575	USD
CY2013	ptct	Deemed Dividend DeemedDividend	-18248768	USD
CY2013	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-37507	USD
CY2013	us-gaap	Paid In Kind Interest PaidInKindInterest	6048580	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	8427188	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	760501	USD
CY2013	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-56091	USD
CY2013	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-48042	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5183412	USD
CY2013	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-285242	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-16554980	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	845732	USD
CY2013	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	60785363	USD
CY2013	us-gaap	Interest Paid InterestPaid	367065	USD
CY2013	ptct	Change In Carrying Value Of Preferred Securities Resulting From Recapitalization ChangeInCarryingValueOfPreferredSecuritiesResultingFromRecapitalization	3390750	USD
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	700000	USD
CY2013	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b>Concentration of risks</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">        The Company has no significant off-balance sheet risk or credit risk concentrations. The Company maintains its cash and cash equivalents with various financial institutions. The Company maintains cash accounts that may at times exceed the federally insured limit; however, it has not experienced and does not anticipate experiencing any credit losses from maintaining cash accounts in excess of such limits.</font></p> <p style="FONT-FAMILY: times;"><font size="2">        The Company's revenues from its two largest collaboration partners and its largest grant as a percentage of total revenues were 80%, 10%, and 8%; 67%, 11%, and 9%; 85%, 8%, and 3%, for 2013, 2012, and 2011, respectively.</font></p> </div>
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	559228	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-328798293	USD
CY2013	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	item
CY2013	ptct	Concentration Risk Number Of Largest Collaboration Partners ConcentrationRiskNumberOfLargestCollaborationPartners	2	item
CY2012Q4	ptct	Deferred Research And Development Costs DeferredResearchAndDevelopmentCosts	200000	USD
CY2013	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-66431593	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20286422	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8280037	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6729364	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	22682827	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	28566459	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29412191	USD
CY2012	us-gaap	Depreciation Depreciation	2704151	USD
CY2013	us-gaap	Depreciation Depreciation	2396405	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3096475	USD
CY2012Q4	ptct	Accrued Consulting And Contracted Research Current AccruedConsultingAndContractedResearchCurrent	2515678	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	621591	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	230999	USD
CY2012Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7023971	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5102795	USD
CY2013Q4	ptct	Accrued Consulting And Contracted Research Current AccruedConsultingAndContractedResearchCurrent	4006336	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1294637	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1123895	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	679720	USD
CY2013Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12207383	USD
CY2013Q3	us-gaap	Repayments Of Debt RepaymentsOfDebt	2600000	USD
CY2013	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-129963	USD
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2011Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2011Q4	ptct	Number Of Members Of Board Of Directors Who Can Be Elected By Holders Of Preferred Stock Voting As Single Class NumberOfMembersOfBoardOfDirectorsWhoCanBeElectedByHoldersOfPreferredStockVotingAsSingleClass	6	item
CY2012Q3	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	160000000	USD
CY2013Q1	ptct	Proceeds From Issuance Of Convertible Preferred Stock And Short Term Debt ProceedsFromIssuanceOfConvertiblePreferredStockAndShortTermDebt	60000000	USD
CY2013	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	3390750	USD
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	600000	shares
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1300000	shares
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-26235102	USD
CY2012	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	159954069	USD
CY2012	us-gaap	Preferred Stock Conversions Inducements PreferredStockConversionsInducements	377787	USD
CY2012	us-gaap	Participating Securities Distributed And Undistributed Earnings ParticipatingSecuritiesDistributedAndUndistributedEarnings	132600000	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	731262	USD
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3328	shares
CY2012	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	13877	shares
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17205	shares
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	219.76
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	42.50
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-51573575	USD
CY2011	us-gaap	Participating Securities Distributed And Undistributed Earnings ParticipatingSecuritiesDistributedAndUndistributedEarnings	30900000	USD
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	26069	USD
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12829411	shares
CY2011	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	4640	shares
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12829411	shares
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.18
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.18
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2288392	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8427188	USD
CY2013Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	21600000	USD
CY2013	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y5M26D
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400	pure
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0565	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0380	pure
CY2011	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0420	pure
CY2013	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0200	pure
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0160	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.4963	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3580	pure
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.4590	pure
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000	pure
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000	pure
CY2011	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0930	pure
CY2011	ptct	Income Tax Benefit On Sale Of Operating Loss And Research And Development Credit IncomeTaxBenefitOnSaleOfOperatingLossAndResearchAndDevelopmentCredit	2300000	USD
CY2013Q4	ptct	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	80387	USD
CY2012Q4	ptct	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	91871	USD
CY2013Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1922332	USD
CY2012Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1535952	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	332539	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1208846	USD
CY2013Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	350447	USD
CY2012Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	6962506	USD
CY2013Q4	ptct	Deferred Tax Assets Tax Credit Federal DeferredTaxAssetsTaxCreditFederal	14081615	USD
CY2012Q4	ptct	Deferred Tax Assets Tax Credit Federal DeferredTaxAssetsTaxCreditFederal	5383092	USD
CY2013Q4	ptct	Deferred Tax Assets Tax Credit State DeferredTaxAssetsTaxCreditState	1587217	USD
CY2012Q4	ptct	Deferred Tax Assets Tax Credit State DeferredTaxAssetsTaxCreditState	1094833	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	88187475	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	71752278	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	10456688	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	7619606	USD
CY2013Q4	ptct	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	12254381	USD
CY2012Q4	ptct	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	10479055	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3211720	USD
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	742341	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	132464801	USD
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	106870380	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	132464801	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	106870380	USD
CY2012	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-9400000	USD
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-25600000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2011	us-gaap	Operating Expenses OperatingExpenses	74830150	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	700000	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	700000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	890000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	849000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	849000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	849000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	952000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	162000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	4551000	USD
CY2013	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.20	pure
CY2013	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05	pure
CY2012	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	USD
CY2011	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	USD
CY2013	dei	Entity Registrant Name EntityRegistrantName	PTC THERAPEUTICS, INC.
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0001070081
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2013Q2	dei	Entity Public Float EntityPublicFloat	260280900	USD
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30076773	shares
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2725702	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	855750	USD
CY2012Q4	ptct	Grant And Other Receivables GrantAndOtherReceivables	1013813	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	4595265	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	145024449	USD
CY2012Q4	ptct	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	197050	USD
CY2012Q4	us-gaap	Assets Assets	13072352	USD
CY2013Q4	us-gaap	Assets Assets	151902821	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4444171	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	16690747	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	28158889	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13133439	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	741667	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2549719	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	438810	USD
CY2012Q4	us-gaap	Liabilities Liabilities	31889085	USD
CY2013Q4	us-gaap	Liabilities Liabilities	15360409	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	131649688	USD
CY2013	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4995763	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	545	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	177583672	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-277224718	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	136542412	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-99640501	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	151902821	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13072352	USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	17000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23803282	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23803282	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4526	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4526	shares
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	34696327	USD
CY2012	ptct	Collaboration Revenue CollaborationRevenue	28779078	USD
CY2012	us-gaap	Revenue From Grants RevenueFromGrants	5166985	USD
CY2012	us-gaap	Sales Revenue Net SalesRevenueNet	33946063	USD
CY2011	ptct	Collaboration Revenue CollaborationRevenue	98960851	USD
CY2011	us-gaap	Revenue From Grants RevenueFromGrants	6451296	USD
CY2011	us-gaap	Sales Revenue Net SalesRevenueNet	105412147	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	46138868	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14615376	USD
CY2012	us-gaap	Operating Expenses OperatingExpenses	60754244	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-26808181	USD
CY2012	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1209577	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26235102	USD
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	28598938	USD
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	58677081	USD
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16153069	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	30581997	USD
CY2011	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2444417	USD
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2305576	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	30904514	USD
CY2012	us-gaap	Profit Loss ProfitLoss	133341180	USD
CY2011	us-gaap	Profit Loss ProfitLoss	30904514	USD
CY2011	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	23.95
CY2011	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.55
CY2011	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1089	shares
CY2011	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5729	shares
CY2013	us-gaap	Operating Expenses OperatingExpenses	80093796	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-45397469	USD
CY2013	us-gaap	Profit Loss ProfitLoss	-66431593	USD
CY2011	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	461358	USD
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1782656	USD
CY2011	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-3606	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26235102	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	30900908	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51503182	USD
CY2011	us-gaap	Depreciation Depreciation	2871200	USD
CY2012	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1782655	USD
CY2011	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-461947	USD
CY2012	us-gaap	Paid In Kind Interest PaidInKindInterest	225730	USD
CY2011	us-gaap	Paid In Kind Interest PaidInKindInterest	416612	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	2288392	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	2816637	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2452430	USD
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1355123	USD
CY2012	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-230315	USD
CY2011	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-2052550	USD
CY2012	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-83817	USD
CY2011	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-214345	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6025483	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3159711	USD
CY2012	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	102757	USD
CY2011	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-67151	USD
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-21972143	USD
CY2011	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-54998713	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-47927791	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-20766787	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	188681	USD
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	165116	USD
CY2013	ptct	Change In Unrealized Loss On Marketable Securities ChangeInUnrealizedLossOnMarketableSecurities	70393	USD
CY2011	ptct	Change In Unrealized Loss On Marketable Securities ChangeInUnrealizedLossOnMarketableSecurities	-3606	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-188681	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	27703048	USD
CY2012	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	6943988	USD
CY2011	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	7185610	USD
CY2012	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	29354752	USD
CY2011	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	5889	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	22410764	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-7179721	USD
CY2012	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-25705708	USD
CY2011	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-243460	USD
CY2012	us-gaap	Interest Paid InterestPaid	1211764	USD
CY2011	us-gaap	Interest Paid InterestPaid	2486682	USD
CY2013	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	12688701	USD
CY2012	ptct	Change In Carrying Value Of Preferred Securities Resulting From Recapitalization ChangeInCarryingValueOfPreferredSecuritiesResultingFromRecapitalization	159954069	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	187439288	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-46922124	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-127828463	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28674870	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28431410	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15414403	USD
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b>Use of estimates</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">        The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p> </div>
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-238604689	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	-272328123	USD
CY2011	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5889	USD
CY2012	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2956829	USD
CY2012	ptct	Adjustments To Additional Paid In Capital Decrease In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStock	159954069	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2288392	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2816637	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8427188	USD
CY2013	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	70393	USD
CY2013	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b>1. The Company</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">        PTC Therapeutics, Inc. (the Company or PTC) was incorporated as a Delaware corporation on March 31, 1998. The Company is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes.</font></p> <p style="FONT-FAMILY: times;"><font size="2">        The Company has devoted substantially all of its efforts to research and development, including clinical trials. The Company has not completed development of any drugs. The Company has not generated product revenue to date and is subject to a number of risks similar to those of other early stage companies, including dependence on key individuals, the difficulties inherent in the development of commercially usable products, the potential need to obtain additional capital necessary to fund the development of its products, and competition from other companies. As of December 31, 2013, the Company had an accumulated deficit of approximately $328.8 million. The Company has financed its operations to date primarily through a public offering in February 2014, its initial public offering in June 2013 (see note 7 below), private placements of its convertible preferred stock, collaborations, bank debt, convertible debt financings, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company's product candidates. The Company believes that its existing cash, cash equivalents, and marketable securities provide for sufficient resources to fund its currently planned operations through 2016.</font></p> </div>
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	70393	USD
CY2013Q4	ptct	Fair Value Assets Transfers Between Level1 And Level2 Amount FairValueAssetsTransfersBetweenLevel1AndLevel2Amount	0	USD
CY2013Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6527.30
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.51
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2013Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.75
CY2012Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5992.61
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	168.00
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1605.53
CY2012Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1380.13
CY2013Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6527.30
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.51
CY2013	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	156044515	USD
CY2011	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2019163	USD
CY2013	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	29061784	USD
CY2011	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	29887327	USD
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2013Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.75
CY2012Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5992.61
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	48.29
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1605.53
CY2012Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1380.13
CY2013Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	2095592	shares
CY2013Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	146340	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	600000	USD
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2816637	USD
CY2011	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-3606	USD
CY2013	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	70393	USD
CY2013	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	70393	USD
CY2013	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2077	USD
CY2012	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2000	USD
CY2011	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2077	USD
CY2010Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3606	USD
CY2013	ptct	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.0590	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.1588	pure
CY2013Q1	us-gaap	Sales Revenue Net SalesRevenueNet	7141664	USD
CY2013Q2	us-gaap	Sales Revenue Net SalesRevenueNet	6854212	USD
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	16289573	USD
CY2013Q4	us-gaap	Sales Revenue Net SalesRevenueNet	4410878	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	15718073	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	21307148	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	20565188	USD
CY2013Q4	us-gaap	Operating Expenses OperatingExpenses	22503387	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8576409	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-14452936	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4275615	USD
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-18092509	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-14684535	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-14586578	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-4416499	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-17885963	USD
CY2013Q1	ptct	Deemed Dividend DeemedDividend	-18248768	USD
CY2013Q1	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	3390750	USD
CY2013Q1	us-gaap	Profit Loss ProfitLoss	-29542553	USD
CY2013Q2	us-gaap	Profit Loss ProfitLoss	-14586578	USD
CY2013Q3	us-gaap	Profit Loss ProfitLoss	-4416499	USD
CY2013Q4	us-gaap	Profit Loss ProfitLoss	-17885963	USD
CY2012Q1	us-gaap	Sales Revenue Net SalesRevenueNet	12525720	USD
CY2012Q2	us-gaap	Sales Revenue Net SalesRevenueNet	7585177	USD
CY2012Q3	us-gaap	Sales Revenue Net SalesRevenueNet	7195076	USD
CY2012Q4	us-gaap	Sales Revenue Net SalesRevenueNet	6640090	USD
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	18745957	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	15083384	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	14250383	USD
CY2012Q4	us-gaap	Operating Expenses OperatingExpenses	12674520	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6220237	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7498207	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7055307	USD
CY2012Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-6034430	USD
CY2013Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	127053124	USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	126982731	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	101888	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	31495	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	127053124	USD
CY2012Q4	us-gaap	Marketable Securities MarketableSecurities	0	USD
CY2013Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	69156819	USD
CY2013Q4	ptct	Available For Sale Securities Debt Maturities Over One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesOverOneYearAmortizedCost	57896305	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	131649688	USD
CY2013	ptct	Adjustments To Additional Paid In Capital Decrease In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStock	-14857927	USD
CY2013	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	162467146	USD

Files In Submission

Name	View Source	Status
0001047469-14-001914-index-headers.html	Edgar Link	pending
0001047469-14-001914-index.html	Edgar Link	pending
0001047469-14-001914.txt	Edgar Link	pending
0001047469-14-001914-xbrl.zip	Edgar Link	pending
a2218675z10-k.htm	Edgar Link	pending
a2218675zex-21_1.htm	Edgar Link	pending
a2218675zex-23_1.htm	Edgar Link	pending
a2218675zex-31_1.htm	Edgar Link	pending
a2218675zex-31_2.htm	Edgar Link	pending
a2218675zex-32_1.htm	Edgar Link	pending
a2218675zex-32_2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g1023778.jpg	Edgar Link	pending
g105379.jpg	Edgar Link	pending
g130374.jpg	Edgar Link	pending
g26502.jpg	Edgar Link	pending
g278232.jpg	Edgar Link	pending
g359549.jpg	Edgar Link	pending
g509564.jpg	Edgar Link	pending
g531272.jpg	Edgar Link	pending
g550991.jpg	Edgar Link	pending
g613392.jpg	Edgar Link	pending
g713834.jpg	Edgar Link	pending
g718207.jpg	Edgar Link	pending
g771729.jpg	Edgar Link	pending
g820632.jpg	Edgar Link	pending
ptct-20131231.xml	Edgar Link	completed
ptct-20131231.xsd	Edgar Link	pending
ptct-20131231_cal.xml	Edgar Link	unprocessable
ptct-20131231_def.xml	Edgar Link	unprocessable
ptct-20131231_lab.xml	Edgar Link	unprocessable
ptct-20131231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTCT
PTC THERAPEUTICS, INC. Stock $ptct

2014 Q1 Form 10-K Financial Statement

#000104746914001914 Filed on March 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTCT PTC THERAPEUTICS, INC. Stock $ptct

2014 Q1 Form 10-K Financial Statement

#000104746914001914 Filed on March 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTCT
PTC THERAPEUTICS, INC. Stock $ptct